BioNTech SE Sponsored ADR (NASDAQ:BNTX) Stock Has Average Price Target of $125.80

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has received a consensus recommendation of “Moderate Buy” from the nineteen ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have issued a hold recommendation, twelve have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $125.80.

A number of equities research analysts have weighed in on BNTX shares. Berenberg Bank set a $140.00 price target on BioNTech in a research report on Wednesday, September 16th. Morgan Stanley cut their price objective on BioNTech from $115.00 to $114.00 and set an “overweight” rating for the company in a report on Wednesday, October 7th. UBS Group reiterated a “buy” rating on shares of BioNTech in a research report on Wednesday, September 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a report on Friday, October 2nd. Finally, Canaccord Genuity Group dropped their target price on BioNTech from $136.00 to $132.00 and set a “buy” rating for the company in a research report on Wednesday, October 14th.

BioNTech Stock Performance

Shares of NASDAQ:BNTX opened at $88.17 on Wednesday. BioNTech has a one year low of $79.52 and a one year high of $124.00. The firm has a market cap of $22.30 billion, a PE ratio of -11.26 and a beta of 1.25. The firm’s 50 day simple moving average is $97.24 and its 200-day simple moving average is $97.20. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%. The firm had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. During the same period in the previous year, the company posted ($1.60) EPS. BioNTech’s quarterly revenue was down 59.5% compared to the same quarter last year. As a group, equities analysts predict that BioNTech will post -6.62 EPS for the current year.

Insider Activity at BioNTech

In related news, CEO Ugur Sahin sold 72,000 shares of BioNTech stock in a transaction on Monday, October 5th. The shares were sold at an average price of $97.23, for a total value of $7,000,560.00. Following the transaction, the chief executive officer owned 108,209 shares in the company, valued at $10,521,161.07. This trade represents a 39.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 807,209 shares of company stock worth $79,246,837. 19.20% of the stock is currently owned by company insiders.

Institutional Trading of BioNTech

Institutional investors have recently added to or reduced their stakes in the business. Flossbach Von Storch SE purchased a new stake in shares of BioNTech during the second quarter valued at approximately $207,142,000. Bank of America Corp DE increased its stake in shares of BioNTech by 22.6% in the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after buying an additional 166,432 shares during the period. First Trust Advisors LP increased its stake in shares of BioNTech by 116.0% in the first quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock worth $74,658,000 after buying an additional 451,124 shares during the period. Assenagon Asset Management S.A. raised its holdings in BioNTech by 79.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 760,675 shares of the company’s stock valued at $74,774,000 after buying an additional 337,412 shares during the last quarter. Finally, SEB Asset Management AB bought a new stake in BioNTech during the 1st quarter valued at $17,804,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing medicines and vaccines based on messenger RNA and other immunotherapy technologies. The company’s research programs address cancer, infectious diseases, and other serious medical conditions.

BioNTech’s oncology portfolio includes individualized and off-the-shelf cancer immunotherapies, including mRNA-based treatments, cell therapies, antibody-based therapies, and immune-modulating approaches. Its infectious-disease activities include vaccine programs developed through proprietary platforms and collaborations.

In collaboration with Pfizer, BioNTech developed Comirnaty, an mRNA-based COVID-19 vaccine.